November 07, 2024
WEST LAFAYETTE, Ind., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, will present at the upcoming Jefferies London Global Healthcare Conference. Beth Taylor, Chief Financial Officer, will participate at the upcoming 15th Annual Craig-Hallum Alpha Select Conference.
Conference Details
Jefferies 2024 London Global Healthcare Conference
Presenter: Robert Leasure Jr., President and Chief Executive Officer
Location: Waldorf-Hilton Hotel, London
Presentation time: Tuesday, November 19th, at 1:30 p.m. GMT (8:30 a.m. ET).
To learn more about the Jefferies event: LINK
The live webcast can be accessed in the “Investors” section of Inotiv’s website and will be archived for approximately 90 days following the event.
15th Annual Craig-Hallum Alpha Select Conference
Date: Tuesday, November 19th
Location: Sheraton NY Times Square Hotel, New York, NY
Beth Taylor is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their Craig-Hallum conference representative.
To learn more about the Craig-Hallum event: LINK
About the Company
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the impact of recent events related to non-human primate matters on the Company’s business, operations, results, financial condition, cash flows, and assets, the Company’s ability to service its outstanding indebtedness and comply with covenants under its credit agreement, compliance with the Resolution and Plea Agreements with the DOJ and the expected impacts on the Company related to the compliance plan, compliance monitor, and the expected financial commitments, changes in the market and demand for the Company’s products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, claims and litigation against or involving the Company, its business and/or its industry, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
Company Contact
Inotiv, Inc
Beth A. Taylor, Chief Financial Officer
(765) 497-8381
beth.taylor@inotiv.com
Investor Relations
LifeSci Advisors
Bob Yedid
(516) 428-8577
bob@lifesciadvisors.com
